Latest Lactams Stories
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slow the progression of some cancers and other diseases of abnormal growth. In the May 23 edition of the prestigious journal Cell, scientists from the University of Montreal explain how they found that the anti-cancer and anti-proliferative drug rapamycin slows down or prevents cells from dividing. “Cells normally monitor the availability of nutrients and will slow down or accelerate their...
Diazepam Addiction Treatment and Drug Rehab Announced by Recovery Associates, Offering Treatment for Those Addicted to Diazepam. WEST PALM BEACH, Fla. (PRWEB) May 21, 2013 Recovery Associates, through its multiple therapeutic tracks, is placing an emphasis upon Diazepam addiction treatment, helping men and women stop using and break free from this harrowing drug. Diazepam is used to treat muscle spasms, anxiety disorder, and seizures. It is also prescribed to control agitation brought on...
“Sleep Brain Waves," developed by Ryan Bolera, is a new insomnia treatment method that reveals the main causes of insomnia and guides on how to treat these causes. A full Sleep Brain Waves review on the site HealthReviewCenter.com indicates if the program is worth buying. Seattle, Wa (PRWEB) May 18, 2013 “Sleep Brain Waves” developed by Ryan Bolera is a new insomnia treatment program that reveals people some main causes of insomnia and ways to treat these causes of insomnia....
Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...
Emergency room visits attributed to sleep aids have increased nearly 220% in recent years, and treatment providers are trying to find solutions to address this growing problem. Malibu, CA (PRWEB) May 14, 2013 According to a recent article in USA Today, the number of emergency room visits attributed to sleep-inducing drugs (particularly Zolpidem, the active ingredient in Ambien) has risen drastically in both numerical scope and severity. According to a report by the Substance Abuse and...
d’Oliveira & Associates wants to inform the public on the continuing risks associates with the Merck Drug and that they now offer a new “No Win No Fee Promise” for those with a Propecia claim. (PRWEB) May 06, 2013 Alleging that the hair loss drug Propecia lead to his prolonged sexual dysfunction, an Illinois man filed a claim against Merck in Pennsylvania Eastern District Court (case no. 2:2013cv00659). According to court documents, on February 5th, 2013 the lawsuit was filed by...
redOrbit Staff & Wire Reports - Your Universe Online Liptruzet, a combination drug developed by Merck that has been found to lower a patient’s low-density lipoprotein (LDL) cholesterol levels, has been approved by the US Food and Drug Administration (FDA). According to MedPage Today Cardiology Editor Chris Kaiser, Liptruzet is a combination of the drugs ezetimibe and atorvastatin and has been approved for the treatment of hyperlipidemia, a condition characterized by abnormally...
On March 28, 2013 B.C. Judge approved a class action lawsuit filed by a man alleging sexual dysfunction from Propecia. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Propecia side effects. San Diego, CA (PRWEB) May 03, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently and is now actively providing expert...
Researchers from CHOP, Penn find better outcomes for efavirenz over nevirapine in children over age 3 in low-resource settings Researchers from The Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more...
Live Webcast from New York on Tuesday, April 30 SAN DIEGO, April 23, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 30, 2013 at 2:20 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can...
